Advancements in Immunotherapy Targeting CLDN6: Unlocking the Potential for Treating CLDN6-Positive Cancers
The field of cancer biology is constantly evolving, leading to advancements in new therapies. One area of interest is immunotherapy, which aims to activate the patient’s immune system to fight cancer cells. However, finding suitable targets on cancer cells while avoiding damage to healthy tissues has been challenging. Recent research has focused on Claudin 6 (CLDN6), a protein selectively expressed in cancer cells that helps them attach to each other. CLDN6 is enriched in various cancers, including non-small cell lung, testicular, and ovarian cancer.